No Data
No Data
Citigroup: Gives a 'buy' rating to Pharmaron (02268) with a target price of HKD 41.
Citigroup initiates a 30-day bullish observation on Joinn Laboratories (02268).
Nomura Adjusts WuXi XDC Cayman's Price Target to HK$28.91 From HK$32.52, Keeps at Buy
WuXi XDC Issues Restricted Shares to Staff
WuXi AppTec (02268.HK) has been approved to grant 4.4969 million restricted shares to 211 grantees.
On July 12th, GLH (02268.HK) announced that under the 2024 stock plan, it had approved the grant of 4,496,948 restricted shares to 211 grantees on July 12th, 2024. Three of the grantees are directors, while the remaining 208 are group employees and must be accepted by selected participants.
Hong Kong stock market anomaly|Yao Ming He Lian (02268) rose more than 5%: ADC drug research and development and active external authorization trading, the company's commercialization is promising.
Zhītōng Finance app learned that Jiangsu Hengrui Medicine (02269) is now up more than 5%, as of the time of publication, up 4.22%, at HKD 15.8, and trading at HKD 17.5152 million. Swhy points out that due to the more precise targeting of ADC drugs compared to traditional small molecules, as well as a wider therapeutic window compared to monoclonal antibody drugs, the ADC drug market is expected to achieve rapid growth; Since the technical path of ADC drugs is clear and commercialization certainty is higher, the number of global ADC drug licensing transactions has grown rapidly since 2022, and the total transaction amount has also significantly increased. The bank pointed out that this was achieved through 'empowerment, follow-up'.
Are Investors Undervaluing WuXi XDC Cayman Inc. (HKG:2268) By 39%?
No Data